Clinical trials: Anthracyclines
Breast Neoplasms
Irinotecan in Patients With Advanced Metastatic Breast Cancer Who Have Experienced Failure of an Anthracycline, a Taxane, and Capecitabine
The purpose of this phase II, randomized, open-label clinical trial is to study 2 schedules of single-agent Irinotecan in women with metastatic breast cancer who have experienced failure of prior therapy with an anthracycline, a…
- Trial name
- NCT00072852
- Testing
- Irinotecan
- Where
- 66 sites in United States, Argentina and 3 more
- Volunteers
- 134 people
- Sponsor
- Pfizer
Breast Neoplasms, Metastases, Neoplasm
This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Metastatic Breast Cancer
The purpose of this study is to assess the efficacy of ZD6474 in patients with metastatic breast cancer at 2 dose levels.
- Trial name
- NCT00034918
- Testing
- ZD6474
- Where
- 2 sites in United States, Spain
- Volunteers
- 44 people
- Sponsor
- Genzyme, a Sanofi Company
Unspecified Adult Solid Tumor, Protocol Specific
GPX-100 in Treating Patients With Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of GPX-100 in treating patients who have solid tumors.
- Trial name
- NCT00003403
- Testing
- GPX-100
- Where
- 2 sites in United States
- Sponsor
- Gem Pharmaceuticals
Breast Cancer
A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Participants With Breast Cancer
This is a study to compare the antitumor activity of ramucirumab (IMC-1121B) and eribulin together versus eribulin alone, in participants with locally recurrent or metastatic breast cancer.
- Trial name
- NCT01427933
- Testing
- Ramucirumab (IMC-1121B), Eribulin
- Where
- 52 sites in United States
- Volunteers
- 141 people
- Sponsor
- Eli Lilly and Company
Cancer
Phase 1/2a Study of SQ3370 in Patients With Advanced Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, and preliminary activity of SQ3370 in patients with advanced solid tumors.
- Trial name
- NCT04106492
- Testing
- SQ3370
- Where
- 10 sites in United States, Australia
- Volunteers
- 53 people
- Sponsor
- Shasqi, Inc.
Breast Cancer, HER2 Positive Breast Cancer
MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients
This study is an open label, randomized, multicenter trial of MM-302 plus trastuzumab. The trial is designed to demonstrate whether MM-302 plus trastuzumab is more effective than the chemotherapy of physician's choice (CPC) plus…
- Trial name
- HERMIONE (NCT02213744)
- Testing
- MM-302, Gemcitabine, Capecitabine
- Where
- 109 sites in United States, Austria and 7 more
- Volunteers
- 113 people
- Sponsor
- Merrimack Pharmaceuticals
Anthracycline Extravasation
Efficacy of TopotectTM (Dexrazoxane) for Accidental Extravasation of Anthracyclines
The purpose of this study is to avoid surgical intervention following extravasation of anthracycline chemotherapy out of a vessel into the surrounding tissues.
- Trial name
- NCT00548561
- Testing
- Dexrazoxane
- Where
- 9 sites in Denmark
- Volunteers
- 23 people
- Sponsor
- Valerio Therapeutics
Locally Recurrent Breast Cancer, Metastatic Breast Cancer
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The study is designed as an open-label, randomized, parallel, two arm, multicenter, international Phase 3 study in patients with recurrent or metastatic breast cancer previously treated with cytotoxic chemotherapy regimens.
- Trial name
- BEACON (NCT01492101)
- Testing
- NKTR-102, Treatment of Physician's Choice (TPC)
- Where
- 153 sites in United States, Belgium and 9 more
- Volunteers
- 852 people
- Sponsor
- Nektar Therapeutics
Advanced Liposarcoma or Leiomyosarcoma
A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma
The purpose of this study is to evaluate whether overall survival for the trabectedin group is superior to the dacarbazine group for patients with advanced L-sarcoma (liposarcoma or leiomyosarcoma).
- Trial name
- NCT01343277
- Testing
- Trabectedin, Dacarbazine
- Where
- 88 sites in United States, Australia and 2 more
- Volunteers
- 579 people
- Sponsor
- Janssen Research & Development, LLC
Metastatic Breast Cancer
A Rollover Study of Ixabepilone (BMS-247550) In Patients With Metastatic Breast Cancer Previously Treated With An Anthracycline
To provide extended access to Ixabepilone therapy to subjects with metastatic breast cancer who have completed the previous Phase II study (CA163-107)
- Trial name
- NCT01027208
- Testing
- Ixabepilone
- Where
- 14 sites in Japan
- Volunteers
- 20 people
- Sponsor
- R-Pharm
Breast Cancer
A Phase II Study of E7389 in Patients With Breast Cancer, Previously Treated With Anthracycline, Taxane and Capecitabine
The purpose of this study is to evaluate the efficacy and safety of E7389 in Patients with locally advanced or metastatic breast cancer, previously treated with anthracycline, taxane, and capecitabine as prior therapy, and who…
- Trial name
- NCT00246090
- Testing
- E7389
- Where
- 65 sites in United States, Canada
- Volunteers
- 298 people
- Sponsor
- Eisai Inc.
Breast Cancer
A Study of Pertuzumab in Combination With Herceptin and Chemotherapy in Participants With HER2-Positive Breast Cancer
This 3 arm study will assess the tolerability, safety and efficacy of 3 neoadjuvant treatment regimens in participants with locally advanced, inflammatory or early stage human epidermal growth factor receptor 2 (HER2)-positive…
- Trial name
- NCT00976989
- Testing
- Pertuzumab, Trastuzumab, FEC
- Where
- 55 sites in Bosnia and Herzegovina, Brazil and 18 more
- Volunteers
- 225 people
- Sponsor
- Hoffmann-La Roche
Advanced Solid Tumors - Phase 1 Population
Safety Study of GPX-150 in Patients With Solid Tumors
This is a Phase 1 safety and dose escalation study to define the maximum tolerated dose (MTD) and identify the dose limiting toxicities (DLT) following IV administration of GPX-150 once every 3 weeks.
- Trial name
- NCT00710125
- Testing
- GPX-150 for Injection
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Gem Pharmaceuticals
Breast Cancer, Metastasis
Study of GPX-100 in the Treatment of Metastatic Breast Cancer
The purpose of this early Phase II multicenter trial is to determine the objective clinical response to GPX-100, an anthracycline similar to doxorubicin, in up to 40 patients with newly diagnosed metastatic breast cancer.
- Trial name
- NCT00123877
- Testing
- GPX-100 (13-deoxydoxorubicin)
- Where
- 3 sites in United States, Bulgaria
- Volunteers
- 40 people
- Sponsor
- Gem Pharmaceuticals
Soft Tissue Sarcoma
Efficacy and Safety Study of GPX-150 to Treat Soft Tissue Sarcoma
This study will assess the safety and efficacy of GPX-150 administered intravenously every 3 weeks in the treatment of patients with soft tissue sarcoma.
- Trial name
- NCT02267083
- Testing
- GPX-150 for Injection
- Where
- 4 sites in United States
- Volunteers
- 22 people
- Sponsor
- Gem Pharmaceuticals
Antiemetic Therapy
Epidemiological EMESIS-Registry
The purpose of this registry is to record information on reality of anti-emetic therapies of cancer-patients in Germany. The outcome of this study is the efficacy of anti-emetic therapies dependent on the rate "complete and major…
- Trial name
- EMESIS (NCT00911222)
- Testing
- non-interventional
- Where
- Germany
- Volunteers
- 1,035 people
- Sponsor
- iOMEDICO AG
Breast Cancer
A Phase I Study of Ixabepilone in Combination With Capecitabine in Japanese Patients With Metastatic Breast Cancer
The purpose of this study is to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) and recommended Phase II dose of ixabepilone in combination with capecitabine in Japanese participants with metastatic…
- Trial name
- NCT00568022
- Testing
- Ixabepilone, Capecitabine
- Where
- 4 sites in Japan
- Volunteers
- 9 people
- Sponsor
- R-Pharm
Breast Cancer, Metastases
Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer
The purpose of this clinical research study is to learn if BMS-247550 added to the approved therapy of capecitabine is better than capecitabine alone in shrinking or slowing the growth of the cancer in women with metastatic…
- Trial name
- NCT00080301
- Testing
- Ixabepilone + Capecitabine, Capecitabine
- Where
- 127 sites in United States, Argentina and 20 more
- Volunteers
- 752 people
- Sponsor
- R-Pharm
Triple-negative Breast Cancer
A Phase II Study of Chiauranib in Combine With Capecitabine in TNBC
This study is to evaluate the preliminary efficacy and safety of chiauranib in combine with capecitabine in advanced triple-negative breast cancer failed to prior anthracyclines and taxanes therapy
- Trial name
- NCT05336721
- Testing
- Chiauranib, capecitabine
- Where
- 4 sites in China
- Volunteers
- 9 people
- Sponsor
- Chipscreen Biosciences, Ltd.
Advanced Breast Cancer
A Randomised,Multi-Center Study of Docetaxol Plus Capecitabine or Cisplatin in Anthracycline-Pretreated Patients With Advanced Breast Cancer
Docetaxol plus capecitabine regimen is the standard treatment for the anthracycline-pretreated patients with advanced breast cancer.
- Trial name
- NCT00717951
- Testing
- docetaxol, cisplatin, capecitabine
- Volunteers
- 120 people
- Sponsor
- Academy Military Medical Science, China